|
Published by: NeuroInsights, LLC
Published: May. 25, 2011 - 563 Pages
Table of Contents- 1: Executive Summary
- The Brain Industry Revealed
- Neuropharmaceuticals
- Neurodevices
- Neurodiagnostics
- Investment Risks and Opportunities
- Translating Neuroscience into Neurotech
- The Neurotech Market Opportunity
- NASDAQ NeuroInsights Neurotech Index
- Neurotechnology and Society
- Key Industry Facts and Findings
- Market Overview
- Industry Overview
- Venture Financing
- Public Market Activity
- Global Growth Drivers
- Other Findings
- 2: Trends and Drivers
- Converging Technology Drivers
- Stem Cells and Neuroregeneration
- Neuroimaging, Diagnostics and Disease Treatment
- Crossing the Blood Brain Barrier
- Demographic Drivers
- More People Living Longer
- Social Drivers
- The Lifestyle Improvement Market
- Medical Tourism
- Economic Drivers
- Global Economic Burden of Brain-Related Illness
- Rising Health Care Costs
- Research Funding
- US Government Research Funding
- Stem Cell Funding
- International Government Research Funding
- Foundations Focus on the Brain
- Regulatory Trends
- World Regulatory Agencies
- Global Clinical Trials
- Intellectual Property Trends
- Global Intellectual Property Protection
- Patent Expirations
- Patent Activity in the United States
- 3: Neuropharmaceutical Sector
- Neuropharmaceutical Sector Overview
- Trends in Neuropharmaceuticals
- Spotlight on Big Pharma
- Neuropharmaceutical Partnering and Licensing
- Neurology Markets and Pipelines
- Alzheimer’s Disease (AD)
- AAMI and MCI
- Epilepsy and Seizure Disorders
- Huntington's disease
- Migraine
- Multiple Sclerosis
- Parkinson’s Disease
- Sleep Disorders
- Restless Legs Syndrome
- Stroke
- Traumatic Brain Injury
- Psychiatry Markets and Pipelines
- Addiction
- Anxiety Disorders
- Attention Disorders
- Depressive Disorders
- Bipolar Disorder
- Obesity
- Schizophrenia
- Cognitive Impairment Associated with Schizophrenia
- Sensory Markets and Pipelines
- Pain
- Retinal Disorders
- 4: Stem Cells and Neuroregeneration
- Defining Stem Cell Markets and Players
- Therapeutics
- Drug Discovery Tools
- Stem Cell Banking
- Stem Cell Approaches
- Background
- The Science of Transplantion
- Controlling Immune Rejection and Infection
- Sources and Harvesting of Stem Cells
- Embronic Stem Cells
- Fetal Stem Cells
- Adult Stem Cells
- Stimulation of Endogenous Stem Cells
- Stem Cells Scientific Hurdles
- Markets and Treatments in Development
- Alzheimer’s Disease
- Amyotrophic Lateral Sclerosis (ALS)
- Hearing Loss
- Huntington’s Disease (HD)
- Multiple Sclerosis (MS)
- Parkinson’s Disease
- Retinal Disorders
- Spinal Cord Injury (SCI)
- Stroke
- Other CNS Diseases
- 5: Neurodevice Sector
- Neurodevice Sector Overview
- Neurodevice Markets
- FDA Classification and Approval Process
- Neurodevice Sector Trends
- Neuroprosthetic Devices
- Cochlear Implants
- Retinal Implants
- Motor Prostheses and Brain Computer Interfaces
- Neuromodulation Devices
- Neuromodulation Device Clinial Trials and Recent Approvals
- Deep Brain Stimulation
- Essential Tremor
- Parkinson’s Disease
- Primary Dystonia
- Severe Obsessive Compulsive Disorder
- Treatment-Resistant Depression
- Epilepsy
- Traumatic Brain Injury and Stroke
- Transcranial Magnetic Stimulation (TMS)
- Alzheimer's
- Treatment Resistant Depression
- Migraine
- Spinal Cord Stimulation (SCS)
- Chronic and Neuropathic Pain
- Spinal Cord Injury
- Vagus Nerve Stimulation (VNS)
- Epilepsy
- Treatment-Resistant Depression
- Obesity
- Peripheral Stimulation
- Balance
- Drug Delivery
- Fecal Incontinence
- Foot Drop
- Hypertension
- Migraine
- Neuropathic Pain
- Restless Legs Syndrome
- Sleep Apnea
- Stroke
- Urinary Conditions
- Gastric Modulation and Obesity
- Neurosurgical devices
- Neurosurgical Navigation and Equipment
- Image Guided Navigation (IGN)
- Intraoperative Magnetic Resonance Imaging (iMRI)
- Automated Surgical Systems
- Brain Monitoring
- Temperature Control Systems
- Neurovascular Intervention
- Ischemic Stroke
- Catheters, Stents and Perfusion devices
- Retrieval and Protection devices
- Ultrasound Thrombolysis
- Hemorrhagic Stroke
- Coils
- Liquid Embolics
- Stents
- Neurosoftware
- Attention Deficit Disorder
- Cognition and Aging
- Emotional Wellbeing
- Learning Disabilities and Autism
- Pain
- The Neurotechnology Industry 2011 Report: Exhibits, Tables, and Charts
- 1-1: Number of Individuals Afflicted by Indication, US and Worldwide, Top 15 Indications
- 1-2: Global Pharmaceutical Sales by Indication, 2010
- 1-3: Neurotechnology Industry Taxonomy
- 1-4: Proportion of Patient Population Segmented by Neurotech Market Opportunity
- 1-5: NASDAQ NeuroInsights Neurotech Index Performance vs. S&P500, NASQAQ Composite, and NASDAQ Biotechnology Index
- 2-1: Projected Percentage Increase in Global Populations aged 65 and over, 1994-2020
- 2-2: Neuropharmaceutical Patent Expirations and Generic Competition, 2003-2015
- 2-3: Neurotechnology Patent Approvals, US, 1985-2007
- 2-4: Neuropharmaceutical Patent Approvals, US, 1985-2007
- 2-5: Neurodevice Patent Approvals, US, 1985-2007
- 2-6: Neurodiagnostic Patent Approvals, US, 1985-2007
- 2-7: Selected US Foundations with a Significant focus on Brain Research and Education
- 2-8: Most Generous Philanthropists for Medical and Brain Research
- 2-9: Global Stem Cell Policy Map
- 3-1: Neuropharmaceutical Revenues by Indication (2010)
- 3-2: FDA Pharmaceutical Approval Process
- 3-3: Big Pharma neuropharmaceutical revenues
- 3-4: Neuropharmaceutical Partnering and Licensing Deals 2004-Q1 2011
- 3-5: Clinical Trials for Alzheimer’s disease (company, compound, phase, mechanism)
- 3-6: Clinical Trials for AAMI and MCI (company, compound, phase, mechanism)
- 3-7: Clinical Trials for Epilepsy (company, compound, phase, mechanism)
- 3-8: Clinical Trials for Huntington’s disease (company, compound, phase, mechanism)
- 3-9: Clinical Trials for Migraine (company, compound, phase, mechanism)
- 3-10: Clinical Trials for Multiple sclerosis (company, compound, phase, mechanism)
- 3-11: Clinical Trials for Parkinson’s disease (company, compound, phase, mechanism)
- 3-12: Clinical Trials for sleep disorders (company, compound, phase, mechanism)
- 3-13: Clinical Trials for stroke Treatment (company, compound, phase, mechanism)
- 3-14: Clinical Trials for traumatic brian injury(company, compound, phase, mechanism)
- 3-15: Number of People with Addiction and Impulse Control Disorders (WW and US)
- 3-16: Clinical Trials for addition and substance abuse (company, compound, phase, mechanism)
- 3-17: Clinical Trials for anxiety disorders (company, compound, phase, mechanism)
- 3-18: Clinical Trials for ADHD (company, compound, phase, mechanism)
- 3-19: Clinical Trials for Depressive disorders (company, compound, phase, mechanism)
- 3-20: Clinical Trials for Obesity Treatment (company, compound, phase, mechanism)
- 3-21: Clinical Trials for Schizophrenia and psychosis (company, compound, phase, mechanism)
- 3-22: Clinical Trials for Retinal disorders (company, compound, phase, mechanism)
- 3-23: Clinical Trials for Nociceptive Pain (company, compound, phase, mechanism)
- 3-23: Clinical Trials for Neuropathic Pain (company, compound, phase, mechanism)
- 4-1: FDA Classification and Approval Process for Medical Devices
- 4-2: Neurodevice Acquisition and Investment Activity: Medtronic, Boston Scientific, J&J
- 4-3: Neurodevice Markets and Revenues (Neuroprosthetic, Neuromodulation, Neurosurgical, Neurofeedback)
- 4-4: Neuromodulation Device Clinical Trials
- 5-1: Neurodiagnostics Markets and Annual Growth (Neuroimaging, In Vitro Diagnostics, Neuroinformatics)
- 5-2: FDA Approval and Insurance Reimbursement of Diagnostics
- 5-3: Neuroimaging Technology (CT, MRI, fMRI, PET, SPECT, EEG, MEG)
- 5-6: Alzheimer’s Disease Neuroimaging Initiative
- 5-7: Neuroinformatics Data Storage
- 5-8: Paul Allen Brain Atlas Project and IBM Blue Brain Project
- 6-1: Total US Venture Capital Investment, 1999-2010
- 6-2: US Life Science Venture Capital Investment, 1999-2010
- 6-3: US Neurotechnology Venture Capital Investment, 1999-2010
- 6-4: Neurotech as Percent of Life Science Venture Investment, 1999-2010
- 6-5: Top Five Neurotechnology Venture Capital Financings, 2001-2010
- 6-6: Top 12 Neurotech Venture Capital Firms with Investments
- 7-1: Neurotechnology Initial Public Offerings US, 2004-Q1 2011
- 7-2: Selected Neurotech M&A Activity, 2004-Q1 2011
- 7-3: Neurotech Index Companies 2011
- 7-4: Neurotech Index Company Fundamentals
- 7-5: Index Company Performance
- 8-1 Leading Neurotechnology Research Centers
- 8-2 Neurotech Research Centers and Affiliated Institutes, Funding, Recent Significant Investments, Reputation, Translation of Discoveries to Industry
- 8-3: UCSF
- 8-4: UCLA
- 8-5: Harvard University
- 8-6: Stanford University
- 8-7: MIT
- 8-8: Columbia University
- 8-9: Washington University
- 8-10: University College London
- 8-11: Karolinska Institute
- 8-12: RIKEN Brain Science Institute
- 9-1 NeuroInsights’ Leading Neurotech Nexus Ratings
- 9-2 Conclusions and Policy Recommendations
- 10-1 Neuropharmaceutical Companies Private Profiles (status, funding, location, investment, descriptions, investors)
- 10-2 Neuropharmaceutical Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
- 10-3 Neurodevice Companies Private Profiles (status, funding, location, investment, descriptions, investors)
- 10-4 Neurodevice Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
- 10-5 Neurodiagnostic Companies Private Profiles (status, funding, location, investment, descriptions, investors)
- 10-6 Neurodiagnostic Companies Public Profiles (status, symbol, HQ, market cap revenues, description)
AbstractDrugs, Biologics, Stem Cells, Devices and Diagnostics for the Brain and Nervous System: Market Analysis and Strategic Investment Guide of the Global Neurological Disease and Psychiatric Illness Markets
Now in its seventh year, The Neurotechnology Industry 2011 Report is an expanded and updated 550 page report of brain and nervous system markets and treatments. It is the only publication to provide a comprehensive pipeline and market analysis to help investors, companies and entrepreneurs easily identify opportunities, understand the competitive landscape, determine risks and understand the dynamics of rapidly changing CNS markets.
The report includes detailed information on products in development globally for over 18 indications at 800 companies including Alzheimer's, addiction, ALS, anxiety, depressive disorders, epilepsy, migraine, mild cognitive impairment, Huntington's, multiple sclerosis, obesity, pain, Parkinson's, schizophrenia, age-related macular degeneration, sensory disorders, sleep disorders, traumatic brain injury and stroke.
Report Highlights
The Neurotechnology Industry 2011 Report provides a unified market-based framework to help executives, investors, and governments easily identify opportunities, understand the competitive landscape and visualize the dynamics of these rapidly growing markets.
- More than 400 profiles of public and private neurotech companies including drugs, devices and diagnostics
- 12 most active neurotech venture capital firms profiled with investments by market segment and U.S. neurotech venture capital trends (1999-Q12011)
- Neurotech IPOs (2004-Q12011), M&A (2004-Q12011), Partnering and Licensing deals (2005-Q12011) and public neurotech stock performance
- Pipelines and market analysis for 18 brain and nervous system illnesses including: addiction, Alzheimer's disease, anxiety, attention disorders, depression, epilepsy, hearing loss, insomnia, mild cognitive impairment, migraine, multiple sclerosis, obesity, pain, Parkinson's disease, retinal disorders, schizophrenia, stroke, and traumatic brain injury
- Analysis of biological basis, current treatment options, and emerging therapeutic strategies
- Analysis of compounds, cell therapies and devices in clinical trials (and abandoned) by company, mechanism of action and stage of development for each indication
- Global and US market size, worldwide revenues for each indication
- Extensive discussion of specific technological, demographic, regulatory and intellectual property trends
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
